Breakthrough Therapy Designation based on promising early clinical evidence observed with daraxonrasib in patients with pancreatic ductal adenocarcinoma (PDAC) RASolute...
CARLSBAD, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, is...
The significant HYPE token position, acquired at an average price of approximately $34 per token, makes Eyenovia the first Nasdaq...
Patient Treated with OneRF® Ablation System Previously Experienced up to 10 Seizures a Day EDEN PRAIRIE, Minn., June 23, 2025...
TORONTO, June 23, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0)...
Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Basal Cell Carcinoma (BCC) Using Novel Doxorubicin Containing...
Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed mean weight reduction in the highest range of...
Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits observed in combination with incretin...
CHICAGO, June 21, 2025 (GLOBE NEWSWIRE) -- Abvance Therapeutics, a biotechnology company developing next generation glucagon analogs and therapies to...
RLT_Angels Photo RLT Angels Association Further founding members include the European Association of Nuclear Medicine (EANM), GE HealthCare, Novartis, and...
From genomics to regulatory innovation, the Kingdom’s presence in Boston establishes it as a major partner in global health scienceBOSTON,...
Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss potential in people with overweight or obesity was...
NEW YORK, June 20, 2025 /PRNewswire/ -- Players such as GE HealthCare, Siemens Healthineers, Philips, and Canon Medical are investing...
Phase 2 highlights robust biomarker identification and survival correlations in first-line metastatic pancreatic cancer (mPDAC) treated with elraglusibCHICAGO and FORT...
Emrosi™ (DFD-29; 40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) demonstrated efficacy independent...
– If approved, nirogacestat will be the first and only therapy with marketing authorization in the EU for the treatment...
Conference is the first-ever international meeting jointly hosted by the Prader-Willi Syndrome Association | USA, the Foundation for Prader-Willi Research,...
MELBOURNE, Australia and INDIANAPOLIS, June 20, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”)...
– Research supports combined use of EEG/ERP and vMRI for accurate differential diagnosis of SCD, MCI and dementia – –...
NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era...